Restenosis

Final Findings From TAXUS I Drug-Eluting Stent Clinical Trial Reported

Published in Blood Weekly, December 20th, 2001

Boston Scientific Corporation (BSX) announced final six-month findings from its TAXUS I clinical trial, including angiographic edge effect analysis and intravascular ultrasound (IVUS) follow-up results.

TAXUS I was designed to assess the safety of a slow-release dose formulation, paclitaxel-eluting coronary stent for the treatment of restenosis. The new data bolster previously reported interim results of zero restenosis and zero thrombosis for the TAXUS I trial, announced on September 24, 2001.

Boston Scientific also provided updates on the progress of the TAXUS II and TAXUS III trials, as well as the status of its submission to the U.S. Food and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry